News

PharmExec1d
Improving the Patient Experience and Lilly’s GI Treatment Pipeline: Q&A with Mark Genovese, MD
Lilly is also developing oral therapies for its gastroenterology pipeline.
Yahoo Finance4mon
FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease
In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced significant improvement in clinical remission and endoscopic response at one year Among those who achieved clinical ...
WebMD4mon
FDA Approves Omvoh for Crohn’s Disease
Jan. 16, 2025 – The FDA has approved the drug Omvoh for treating adults with moderately to severely active Crohn's disease, a type of chronic inflammatory bowel disease. This marks the second ...
pharmaphorum1d
Lilly nets a second FDA okay for Omvoh, in Crohn's disease
Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.
Hosted on MSN4mon
FDA Okays LLY's Omvoh for Second Inflammatory Bowel Disease Condition
Omvoh was approved for its first IBD indication, moderately to severely active ulcerative colitis (“UC”), in 2023. The drug is currently approved for UC in 44 countries.
Hosted on MSN5mon
Lilly gets positive EU regulatory opinion for Omvoh for Crohn's
Lilly (NYSE:LLY) has also applied to have Omvoh approved by the FDA for the treatment of moderately to severely active Crohn's disease. A decision expected in the first half of 2025.